NASDAQ · BJDX
Healthcare · Medical - Devices
$1.01
Down-$0.11 (-11.16%)
Updated Sep 11, 2026, 8:13 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BJDX closed at $1.01 after 20 trading sessions, down 4.72% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $0.97 | $1.0186 | $0.9621 | $1.01 | 308.36K |
| Sep 9, 2026 | $1.01 | $1.08 | $0.89 | $1.01 | 1.45M |
| Sep 8, 2026 | $1.025 | $1.09 | $0.912 | $1.03 | 46.23M |
| Sep 4, 2026 | $0.8403 | $0.8496 | $0.8211 | $0.8324 | 92K |
| Sep 3, 2026 | $0.84 | $0.8598 | $0.82 | $0.8489 | 143.37K |
| Sep 2, 2026 | $0.8499 | $0.8699 | $0.818 | $0.8491 | 270.91K |
| Sep 1, 2026 | $0.8339 | $0.8598 | $0.8227 | $0.8475 | 177.25K |
| Aug 31, 2026 | $0.906 | $0.906 | $0.8331 | $0.87 | 544.71K |
| Aug 28, 2026 | $0.92 | $1.239 | $0.8843 | $0.90 | 11.37M |
| Aug 27, 2026 | $0.8844 | $0.9298 | $0.8844 | $0.9095 | 145.94K |
| Aug 26, 2026 | $0.9217 | $0.9461 | $0.8901 | $0.8934 | 82.34K |
| Aug 25, 2026 | $0.91 | $0.96 | $0.90 | $0.9162 | 124.21K |
| Aug 24, 2026 | $0.93 | $0.93 | $0.892 | $0.9002 | 84.28K |
| Aug 21, 2026 | $0.9277 | $0.9475 | $0.90 | $0.9109 | 120.32K |
| Aug 20, 2026 | $0.946 | $0.96 | $0.916 | $0.9393 | 159.88K |
| Aug 19, 2026 | $0.99 | $1.04 | $0.9441 | $0.9601 | 530.6K |
| Aug 18, 2026 | $0.996 | $0.996 | $0.945 | $0.9701 | 278.4K |
| Aug 17, 2026 | $1.04 | $1.0497 | $0.9762 | $1.02 | 386.88K |
| Aug 14, 2026 | $1.08 | $1.09 | $1.03 | $1.05 | 166.49K |
| Aug 13, 2026 | $1.00 | $1.07 | $1.00 | $1.06 | 268.3K |
The latest Smart Investors Daily articles mentioning BJDX.
BJDX research
Company profile and research snapshot.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2023 | Dawson James | Neutral | — |
| Jan 12, 2022 | Dawson James | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 21, 2026
Bluejay Diagnostics, Inc. (NASDAQ:BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the successful completion of patient enrollment in its
Benzinga · Jul 20, 2026
Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares
Benzinga · Jul 17, 2026
Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-market session. The market value of their outstanding shares is at $5.1 million. Advanced Biomed (NASDAQ:ADVB) shares
Benzinga · Mar 6, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BJDX.
